Persistence of antibiotic resistant bacteria.

Bacterial adaptation to antibiotics has been very successful and over the past decade the increase in antibiotic resistance has generated considerable medical problems. Even though many drug resistances confer a fitness cost, suggesting that they might disappear by reducing the volume of antibiotic use, increasing evidence obtained from laboratory and epidemiological studies indicate that several processes will act to cause long-term persistence of resistant bacteria. Compensatory evolution that ameliorates the costs of resistance, the occurrence of cost-free resistances and genetic linkage between non-selected and selected resistances will confer a stabilization of the resistant bacteria. Thus, it is of importance that we forcefully implement strategies to reduce the rate of appearance and spread of resistant bacteria to allow new drug discovery to catch up with bacterial resistance development.

[1]  G. Bierbaum,et al.  An Elevated Mutation Frequency Favors Development of Vancomycin Resistance in Staphylococcus aureus , 2002, Antimicrobial Agents and Chemotherapy.

[2]  F. Taddei,et al.  Mutator Bacteria as a Risk Factor in Treatment of Infectious Diseases , 2002, Antimicrobial Agents and Chemotherapy.

[3]  O. Cars,et al.  Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. , 2003, The Journal of antimicrobial chemotherapy.

[4]  F. Taddei,et al.  High Frequency of Mutator Strains among Human Uropathogenic Escherichia coli Isolates , 2002, Journal of bacteriology.

[5]  J. Roth,et al.  Amplification–mutagenesis: Evidence that “directed” adaptive mutation and general hypermutability result from growth with a selected gene amplification , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Oliver,et al.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. , 2000, Science.

[7]  J. Roth,et al.  Formation of an F′ Plasmid by Recombination between Imperfectly Repeated Chromosomal Rep Sequences: a Closer Look at an Old Friend (F′128pro lac) , 2003, Journal of bacteriology.

[8]  Ted Cohen,et al.  The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.

[9]  J. Miller,et al.  Proliferation of mutators in A cell population , 1997, Journal of bacteriology.

[10]  Lars Liljas,et al.  Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium , 2002, Molecular microbiology.

[11]  J. Roth,et al.  The effect of genomic position on reversion of a lac frameshift mutation (lacIZ33) during non‐lethal selection (adaptive mutation) , 2002, Molecular microbiology.

[12]  Carl T. Bergstrom,et al.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Buckling,et al.  Phenotypic switching of antibiotic resistance circumvents permanent costs in Staphylococcus aureus , 2001, Current Biology.

[14]  A. Sundsfjord,et al.  Stability, persistence, and evolution of plasmid-encoded VanA glycopeptide resistance in enterococci in the absence of antibiotic selection in vitro and in gnotobiotic mice. , 2002, Microbial drug resistance.

[15]  O. Berg,et al.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Anderson,et al.  The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Furusawa,et al.  A conspicuous adaptability to antibiotics in the Escherichia coli mutator strain, dnaQ49. , 1999, FEMS microbiology letters.

[18]  M G Reynolds,et al.  Compensatory evolution in rifampin-resistant Escherichia coli. , 2000, Genetics.

[19]  L. Ren,et al.  Escherichia coli Cells Exposed to Streptomycin Display a Mutator Phenotype , 1999, Journal of bacteriology.

[20]  T. Wichelhaus,et al.  Biological Cost of Rifampin Resistance from the Perspective of Staphylococcus aureus , 2002, Antimicrobial Agents and Chemotherapy.

[21]  E. Böttger,et al.  Fitness Cost of Chromosomal Drug Resistance-Conferring Mutations , 2002, Antimicrobial Agents and Chemotherapy.

[22]  J. Roth,et al.  Evidence that selected amplification of a bacterial lac frameshift allele stimulates Lac(+) reversion (adaptive mutation) with or without general hypermutability. , 2002, Genetics.

[23]  S. Cole,et al.  Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans , 2002, Infection and Immunity.

[24]  S. Rosenberg,et al.  Adaptive mutations, mutator DNA polymerases and genetic change strategies of pathogens. , 2001, Current opinion in microbiology.

[25]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[26]  D. Andersson,et al.  Biological cost and compensatory evolution in fusidic acid‐resistant Staphylococcus aureus , 2001, Molecular microbiology.

[27]  Levin Br.  Models for the spread of resistant pathogens. , 2002 .

[28]  S. Gillespie,et al.  Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. , 2002, Microbial drug resistance.

[29]  O. Berg,et al.  Regulating general mutation rates: examination of the hypermutable state model for Cairnsian adaptive mutation. , 2003, Genetics.

[30]  O. Berg,et al.  Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. , 2000, Science.

[31]  D. Livermore,et al.  Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction , 2001, The Lancet.

[32]  F. Baquero,et al.  Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. , 2002, The Journal of antimicrobial chemotherapy.

[33]  S. Gillespie,et al.  Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. , 2000, The Journal of infection.

[34]  J. Barbé,et al.  Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. , 1990, Mutagenesis.

[35]  J. G. D. Visser,et al.  The fate of microbial mutators. , 2002 .

[36]  B. Levin,et al.  Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. , 2000, Genetics.

[37]  S. Knudsen,et al.  The frequency of mutators in populations of Escherichia coli. , 2000, Mutation research.

[38]  S. Gillespie,et al.  Physiological Cost of Rifampin Resistance Induced In Vitro in Mycobacterium tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[39]  F. Vandenesch,et al.  Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals. , 2001, The Journal of antimicrobial chemotherapy.